Acute lymphoblastic leukemia and developmental biology: A crucial interrelationship

Cell Cycle

Volumn 10, Issue 20, 2011, Pages 3473-3486

  Campos Sanchez, Elena ^a   Toboso Navasa, Amparo ^a   Romero Camarero, Isabel ^b   Barajas Diego, Marcos ^b   Sanchez Garcia, Isidro ^b   Cobaleda, Cesar ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

B ALL; B cells; Cancer; Developmental plasticity; Hematopoietic development; Leukemia; Leukemic stem cells; Lymphopoiesis; Stem cells

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CANCER RESEARCH; CANCER STEM CELL; CELL DIFFERENTIATION; DEVELOPMENTAL BIOLOGY; DISEASE ASSOCIATION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PLASTICITY; REVIEW;

EID: 80055106332     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.20.17779     Document Type: Review

References (185)

1. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429:464-8; PMID:15164072; DOI:10.1038/ nature02626.
2. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006; 6:193-203; PMID:16467884; DOI:10.1038/nrc1816.
3. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371:1030-43; PMID:18358930; DOI:10.1016/S0140-6736(08)60457-2.
4. Purton LE, Scadden DT. Limiting factors in murine hematopoietic stem cell assays. Cell Stem Cell 2007; 1:263-70; PMID:18371361; DOI:10.1016/j.stem.2007. 08.016.
5. Welner RS, Pelayo R, Kincade PW. Evolving views on the genealogy of B cells. Nat Rev Immunol 2008; 8:95-106; PMID:18204470; DOI:10.1038/nri2234.
6. Li CL, Johnson GR. Murine hematopoietic stem and progenitor cells: I. Enrichment and biologic characterization. Blood 1995; 85:1472-9; PMID:7534130.
7. Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1994; 1:661-73; PMID:7541305; DOI:10.1016/1074-7613(94)90037-X.
8. low/negative hematopoietic stem cell. Science 1996; 273:242-5; PMID:8662508; DOI:10.1126/science.273.5272.242.
9. Zhao Y, Lin Y, Zhan Y, Yang G, Louie J, Harrison DE, et al. Murine hematopoietic stem cell characterization and its regulation in BM transplantation. Blood 2000; 96:3016-22; PMID:11049979.
10. Adolfsson J, Borge OJ, Bryder D, Theilgaard-Monch K, Astrand-Grundstrom I, Sitnicka E, et al. Upregulation of Flt3 expression within the bone marrow Lin(-) Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 2001; 15:659-69; PMID:11672547; DOI:10.1016/S1074-7613(01)00220-5.
11. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci USA 2001; 98:14541-6; PMID:11724967; DOI:10.1073/pnas.261562798.
12. + multipotent hematopoietic progenitors. Cell 2006; 126:415-26; PMID:16873070; DOI:10.1016/j.cell.2006.06.037.
13. + hematopoietic stem cells. Stem Cells 2006; 24:1087-94; PMID:16373693; DOI:10.1634/stemcells.2005-0396.
14. Benveniste P, Frelin C, Janmohamed S, Barbara M, Herrington R, Hyam D, et al. Intermediate-term hematopoietic stem cells with extended but time-limited reconstitution potential. Cell Stem Cell 2010; 6:48-58; PMID:20074534; DOI:10.1016/j.stem.2009.11.014.
15. Müller-Sieburg CE, Cho RH, Thoman M, Adkins B, Sieburg HB. Deterministic regulation of hematopoietic stem cell self-renewal and differentiation. Blood 2002; 100:1302-9; PMID:12149211.
16. Chang HH, Hemberg M, Barahona M, Ingber DE, Huang S. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 2008; 453:544-7; PMID:18497826; DOI:10.1038/nature06965.
17. Hu M, Krause D, Greaves M, Sharkis S, Dexter M, Heyworth C, et al. Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev 1997; 11:774-85; PMID:9087431; DOI:10.1101/gad.11.6.774.
18. Månsson R, Hultquist A, Luc S, Yang L, Anderson K, Kharazi S, et al. Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity 2007; 26:407-19; PMID:17433729; DOI:10.1016/j.immuni.2007.02.013.
19. Enver T, Pera M, Peterson C, Andrews PW. Stem cell states, fates and the rules of attraction. Cell Stem Cell 2009; 4:387-97; PMID:19427289; DOI:10.1016/j.stem.2009.04.011.
20. Huang S, Ernberg I, Kauffman S. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol 2009; 20:869-76; PMID:19595782; DOI:10.1016/j.semcdb.2009.07.003.
21. Huang S. On the intrinsic inevitability of cancer: From foetal to fatal attraction. Semin Cancer Biol 2011; PMID: 21640825.
22. Abollo-Jiménez F, Jimenez R, Cobaleda C. Physiological cellular reprogramming and cancer. Semin Cancer Biol 2010; 20:98-106; PMID:20188173; DOI:10.1016/j.semcancer.2010.02.002.
23. Adolfsson J, Mansson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen CT, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 2005; 121:295-306; PMID:15851035; DOI:10.1016/j.cell.2005.02. 013.
24. Igarashi H, Gregory SC, Yokota T, Sakaguchi N, Kincade PW. Transcription from the RAG1 locus marks the earliest lymphocyte progenitors in bone marrow. Immunity 2002; 17:117-30; PMID:12196284; DOI:10.1016/S1074-7613(02)00366-7.
25. Ichii M, Shimazu T, Welner RS, Garrett KP, Zhang Q, Esplin BL, et al. Functional diversity of stem and progenitor cells with B-lymphopoietic potential. Immunol Rev 2010; 237:10-21; PMID:20727026; DOI:10.1111/j.1600-065X. 2010.00933.x.
26. Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 1997; 91:661-72; PMID:9393859; DOI:10.1016/S0092-8674(00)80453-5.
27. Izon D, Rudd K, DeMuth W, Pear WS, Clendenin C, Lindsley RC, et al. A common pathway for dendritic cell and early B cell development. J Immunol 2001; 167:1387-92; PMID:11466357.
28. Rumfelt LL, Zhou Y, Rowley BM, Shinton SA, Hardy RR. Lineage specification and plasticity in CD19- early B cell precursors. J Exp Med 2006; 203:675-87; PMID:16505143; DOI:10.1084/jem.20052444.
29. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991; 173:1213-25; PMID:1827140; DOI:10.1084/jem.173.5.1213.
30. Hardy RR, Kincade PW, Dorshkind K. The protean nature of cells in the B lymphocyte lineage. Immunity 2007; 26:703-14; PMID:17582343; DOI:10.1016/j.immuni.2007.05.013.
31. - hematopoietic progenitor with potent lymphoid and myeloid developmental potential. Eur J Immunol 2005; 35:2019-30; PMID:15971276; DOI:10.1002/eji.200526318.
32. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007; 8:463-70; PMID:17440452; DOI:10.1038/ni1454.
33. Majeti R, Park CY, Weissman IL. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 2007; 1:635-45; PMID:18371405; DOI:10.1016/j.stem.2007.10.001.
34. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19:138-52; PMID:21251617; DOI:10.1016/j.ccr.2010.12. 012.
35. Majeti R, Weissman IL. Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye. Cancer Cell 2011; 19:9-10; PMID:21251611; DOI:10.1016/j.ccr.2011.01.007.
36. Galy A, Travis M, Cen D, Chen B, Human TB. Natural killer and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995; 3:459-73; PMID:7584137; DOI:10.1016/1074-7613(95)90175-2.
37. Haddad R, Guardiola P, Izac B, Thibault C, Radich J, Delezoide AL, et al. Molecular characterization of early human T/NK and B-lymphoid progenitor cells in umbilical cord blood. Blood 2004; 104:3918- 26; PMID:15331438; DOI:10.1182/blood-2004-05-1845.
38. Miller JS, McCullar V, Punzel M, Lemischka IR, Moore KA. Single adult human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells and myeloid cells. Blood 1999; 93:96-106; PMID:9864151.
39. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125:315-26; PMID:16630819; DOI:10.1016/j.cell.2006.02.041.
40. Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev Genet 2007; 8:263-71; PMID:17363975; DOI:10.1038/nrg2046.
41. Weishaupt H, Sigvardsson M, Attema JL. Epigenetic chromatin states uniquely define the developmental plasticity of murine hematopoietic stem cells. Blood 2010; 115:247-56; PMID:19887676; DOI:10.1182/blood-2009-07-235176.
42. Ng SY, Yoshida T, Zhang J, Georgopoulos K. Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. Immunity 2009; 30:493-507; PMID:19345118; DOI:10.1016/j.immuni.2009.01.014.
43. Thompson EC, Cobb BS, Sabbattini P, Meixlsperger S, Parelho V, Liberg D, et al. Ikaros DNA-binding proteins as integral components of B cell developmental- stage-specific regulatory circuits. Immunity 2007; 26:335-44; PMID:17363301; DOI:10.1016/j. immuni.2007.02.010.
44. Reynaud D, Demarco IA, Reddy KL, Schjerven H, Bertolino E, Chen Z, et al. Regulation of B cell fate commitment and immunoglobulin heavy-chain gene rearrangements by Ikaros. Nat Immunol 2008; 9:927-36; PMID:18568028; DOI:10.1038/ni.1626.
45. Spooner CJ, Cheng JX, Pujadas E, Laslo P, Singh H. A recurrent network involving the transcription factors PU.1 and Gfi1 orchestrates innate and adaptive immune cell fates. Immunity 2009; 31:576-86; PMID:19818654; DOI:10.1016/j.immuni.2009.07.011.
46. Arinobu Y, Mizuno S, Chong Y, Shigematsu H, Iino T, Iwasaki H, et al. Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. Cell Stem Cell 2007; 1:416-27; PMID:18371378; DOI:10.1016/j.stem.2007.07.004.
47. DeKoter RP, Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 2000; 288:1439-41; PMID:10827957; DOI:10.1126/science.288.5470.1439.
48. Nutt SL, Metcalf D, D'Amico A, Polli M, Wu L. Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J Exp Med 2005; 201:221-31; PMID:15657291; DOI:10.1084/jem.20041535.
49. Li H, Ji M, Klarmann KD, Keller JR. Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development. Blood 2010; 116:1060-9; PMID:20453161; DOI:10.1182/blood-2009-11-255075.
50. Murre C. Helix-loop-helix proteins and lymphocyte development. Nat Immunol 2005; 6:1079-86; PMID:16239924; DOI:10.1038/ni1260.
51. Bain G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, Weintraub BC, et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 1994; 79:885-92; PMID:8001125; DOI:10.1016/0092-8674(94)90077-9.
52. Borghesi L, Aites J, Nelson S, Lefterov P, James P, Gerstein R. E47 is required for V(D)J recombinase activity in common lymphoid progenitors. J Exp Med 2005; 202:1669-77; PMID:16365147; DOI:10.1084/jem.20051190.
53. Zhuang Y, Soriano P, Weintraub H. The helix-loop-helix gene E2A is required for B cell formation. Cell 1994; 79:875-84; PMID:8001124; DOI:10.1016/0092-8674(94)90076-0.
54. Roessler S, Gyory I, Imhof S, Spivakov M, Williams RR, Busslinger M, et al. Distinct promoters mediate the regulation of Ebf1 gene expression by interleukin- 7 and Pax5. Mol Cell Biol 2007; 27:579-94; PMID:17101802; DOI:10.1128/MCB.01192-06.
55. Smith EM, Gisler R, Sigvardsson M. Cloning and characterization of a promoter flanking the early B cell factor (EBF) gene indicates roles for E-proteins and autoregulation in the control of EBF expression. J Immunol 2002; 169:261-70; PMID:12077253.
56. Seet CS, Brumbaugh RL, Kee BL. Early B cell factor promotes B lymphopoiesis with reduced interleukin 7 responsiveness in the absence of E2A. J Exp Med 2004; 199:1689-700; PMID:15210745; DOI:10.1084/jem.20032202.
57. O'Riordan M, Grosschedl R. Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. Immunity 1999; 11:21-31; PMID:10435576; DOI:10.1016/S1074-7613(00)80078-3.
58. Sigvardsson M, O'Riordan M, Grosschedl R. EBF and E47 collaborate to induce expression of the endogenous immunoglobulin surrogate light chain genes. Immunity 1997; 7:25-36; PMID:9252117; DOI:10.1016/S1074-7613(00)80507-5.
59. Romanow WJ, Langerak AW, Goebel P, Wolvers-Tettero IL, van Dongen JJ, Feeney AJ, et al. E2A and EBF act in synergy with the V(D)J recombinase to generate a diverse immunoglobulin repertoire in nonlymphoid cells. Mol Cell 2000; 5:343-53; PMID:10882075; DOI:10.1016/S1097-2765(00)80429-3.
60. Kwon K, Hutter C, Sun Q, Bilic I, Cobaleda C, Malin S, et al. Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity 2008; 28:751-62; PMID:18538592; DOI:10.1016/j.immuni.2008.04.014.
61. Pongubala JM, Northrup DL, Lancki DW, Medina KL, Treiber T, Bertolino E, et al. Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5. Nat Immunol 2008; 9:203-15; PMID:18176567; DOI:10.1038/ni1555.
62. Sigvardsson M, Clark DR, Fitzsimmons D, Doyle M, Akerblad P, Breslin T, et al. Early B-cell factor, E2A and Pax-5 cooperate to activate the early B cell-specific mb-1 promoter. Mol Cell Biol 2002; 22:8539-51; PMID:12446773; DOI:10.1128/MCB.22.24.8539-51.2002.
63. Zandi S, Mansson R, Tsapogas P, Zetterblad J, Bryder D, Sigvardsson M. EBF1 is essential for B-lineage priming and establishment of a transcription factor network in common lymphoid progenitors. J Immunol 2008; 181:3364-72; PMID:18714008.
64. Carotta S, Holmes ML, Pridans C, Nutt SL. Pax5 maintains cellular identity by repressing gene expression throughout B cell differentiation. Cell Cycle 2006; 5:2452-6; PMID:17102626; DOI:10.4161/cc.5.21.3396.
65. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999; 401:556- 62; PMID:10524622; DOI:10.1038/44076.
66. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 2006; 24:269-81; PMID:16546096; DOI:10.1016/j.immuni.2006.01.012.
67. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration and immune function. Immunity 2007; 27:49-63; PMID:17658281; DOI:10.1016/j.immuni.2007.05.019.
68. Fuxa M, Busslinger M. Reporter gene insertions reveal a strictly B lymphoid-specific expression pattern of Pax5 in support of its B cell identity function. J Immunol 2007; 178:8222-8; PMID:17600970.
69. Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 2007; 449:473-7; PMID:17851532; DOI:10.1038/nature06159.
70. Decker T, Pasca di Magliano M, McManus S, Sun Q, Bonifer C, Tagoh H, et al. Stepwise activation of enhancer and promoter regions of the B cell commitment gene Pax5 in early lymphopoiesis. Immunity 2009; 30:508-20; PMID:19345119; DOI:10.1016/j.immuni.2009.01.012.
71. McManus S, Ebert A, Salvagiotto G, Medvedovic J, Sun Q, Tamir I, et al. The transcription factor Pax5 regulates its target genes by recruiting chromatinmodifying proteins in committed B cells. EMBO J 2011; 30:2388-404; PMID:21552207; DOI:10.1038/emboj.2011.140.
72. von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995; 181:1519-26; PMID:7699333; DOI:10.1084/jem.181.4.1519.
73. Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)- dependent cytokines interleukins 2, 4, 7, 9, 15 and 21, and their signaling pathways. Immunol Rev 2004; 202:67-83; PMID:15546386; DOI:10.1111/j.0105-2896.2004.00203.x.
74. Sudo T, Nishikawa S, Ohno N, Akiyama N, Tamakoshi M, Yoshida H. Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc Natl Acad Sci USA 1993; 90:9125-9; PMID:8415665; DOI:10.1073/pnas.90.19. 9125.
75. Kikuchi K, Kasai H, Watanabe A, Lai AY, Kondo M. IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expression. J Immunol 2008; 181:383-92; PMID:18566404.
76. Kikuchi K, Lai AY, Hsu CL, Kondo M. IL-7 receptor signaling is necessary for stage transition in adult B cell development through upregulation of EBF. J Exp Med 2005; 201:1197-203; PMID:15837809; DOI:10.1084/jem.20050158.
77. Miller JP, Izon D, DeMuth W, Gerstein R, Bhandoola A, Allman D. The earliest step in B lineage differentiation from common lymphoid progenitors is critically dependent upon interleukin 7. J Exp Med 2002; 196:705-11; PMID:12208884; DOI:10.1084/jem.20020784.
78. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008; 22:711-21; PMID:18347089; DOI:10.1101/gad.1643908.
79. Malin S, McManus S, Cobaleda C, Novatchkova M, Delogu A, Bouillet P, et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 2010; 11:171-9; PMID:19946273; DOI:10.1038/ni.1827.
80. Malin S, McManus S, Busslinger M. STAT5 in B cell development and leukemia. Curr Opin Immunol 2010; 22:168-76; PMID:20227268; DOI:10.1016/j.coi. 2010.02.004.
81. Fleming HE, Paige CJ. Pre-B cell receptor signaling mediates selective response to IL-7 at the pro-B to pre-B cell transition via an ERK/MAP kinase-dependent pathway. Immunity 2001; 15:521-31; PMID:11672535; DOI:10.1016/S1074-7613(01)00216-3.
82. Bergman Y, Cedar H. Epigenetic control of recombination in the immune system. Semin Immunol 2010; 22:323-9; PMID:20832333; DOI:10.1016/j.smim.2010.07. 003.
83. Hewitt SL, Chaumeil J, Skok JA. Chromosome dynamics and the regulation of V(D)J recombination. Immunol Rev 2010; 237:43-54; PMID:20727028; DOI:10.1111/j.1600-065X.2010.00931.x.
84. Schatz DG, Ji Y. Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol 2011; 11:251-63; PMID:21394103; DOI:10.1038/nri2941.
85. Vettermann C, Schlissel MS. Allelic exclusion of immunoglobulin genes: models and mechanisms. Immunol Rev 2010; 237:22-42; PMID:20727027; DOI:10.1111/j.1600-065X.2010.00935.x.
86. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. Immunol Rev 2010; 237:140-59; PMID:20727034; DOI:10.1111/j.1600-065X.2010.00940.x.
87. Hjalgrim LL, Rostgaard K, Schmiegelow K, Soderhall S, Kolmannskog S, Vettenranta K, et al. Age- and sexspecific incidence of childhood leukemia by immunophenotype in the Nordic countries. J Natl Cancer Inst 2003; 95:1539-44; PMID:14559876.
88. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350:1535-48; PMID:15071128; DOI:10.1056/NEJMra023001.
89. LeBien TW. Fates of human B-cell precursors. Blood 2000; 96:9-23; PMID:10891425.
90. Sánchez I, San Miguel JF, Corral J, Martin C, Perez R, Gonzalez M, et al. Gene rearrangement in acute nonlymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. Br J Haematol 1995; 89:104-9; PMID:7530475.
91. Sánchez-García I, San Miguel JF, Gonzalez-Sarmiento R. Immunoglobulin lambda chain gene rearrangement in a case of acute nonlymphoblastic leukemia. Leukemia 1999; 13:485-7; PMID:10086742; DOI:10.1038/sj.leu.2401204.
92. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003; 3:639-49; PMID:12951583; DOI:10.1038/nrc1164.
93. Cobaleda C, Sanchez-Garcia I. B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays 2009; 31:600-9; PMID:19444834; DOI:10.1002/bies.200800234.
94. Sánchez-García I, Vicente-Duenas C, Cobaleda C. The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice? Bioessays 2007; 29:1269-80; PMID:18022789; DOI:10.1002/bies.20679.
95. Vormoor HJ. Malignant stem cells in childhood acute lymphoblastic leukemia: the stem cell concept revisited. Cell Cycle 2009; 8:996-9; PMID:19270513; DOI:10.4161/cc.8.7.7984.
96. Crooks GM, Weinberg K. The unpredictable stem cell. Nat Immunol 2006; 7:1129-30; PMID:17053793; DOI:10.1038/ni1106-29.
97. McKenzie JL, Gan OI, Doedens M, Wang JC, Dick JE. Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol 2006; 7:1225-33; PMID:17013390; DOI:10.1038/ni1393.
98. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5:738-43; PMID:15170211; DOI:10.1038/ni1080.
99. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469:356-61; PMID:21160474; DOI:10.1038/nature09650.
100. Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A, et al. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood 2011; 117:2658-67; PMID:21224468; DOI:10.1182/blood-2010-03-275347.
101. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008; 322:1377-80; PMID:19039135; DOI:10.1126/science.1164266.
102. van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempski H, et al. Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood 2011; 117:6247-54; PMID:21482711; DOI:10.1182/blood-2010-10-314674.
103. Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA, et al. Evolution of human BCRABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469:362-7; PMID:21248843; DOI:10.1038/nature09733.
104. Greaves M. Cancer stem cells: back to Darwin? Semin Cancer Biol 2010; 20:65-70; PMID:20359535; DOI:10.1016/j.semcancer.2010.03.002.
105. Barabé F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science 2007; 316:600-4; PMID:17463288; DOI:10.1126/science.1139851.
106. Xie H, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. Cell 2004; 117:663-76; PMID:15163413; DOI:10.1016/S0092-8674(04) 00419-2.
107. Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig M, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008; 133:250-64; PMID:18423197; DOI:10.1016/j.cell.2008.03. 028.
108. Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, Raffeld M, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood 2008; 111:5433-9; PMID:18272816; DOI:10.1182/blood-2007-11-124792.
109. Shao H, Xi L, Raffeld M, Feldman AL, Ketterling RP, Knudson R, et al. Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Mod Pathol 2011; PMID: 21666687.
110. Janz M, Dorken B, Mathas S. Reprogramming of B lymphoid cells in human lymphoma pathogenesis. Cell Cycle 2006; 5:1057-61; PMID:16687930; DOI:10.4161/cc.5.10.2737.
111. Mathas S, Janz M, Hummel F, Hummel M, Wollert- Wulf B, Lusatis S, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2006; 7:207-15; PMID:16369535; DOI:10.1038/ni1285
112. le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008; 14:47-58; PMID:18598943; DOI:10.1016/j.ccr.2008.05.015.
113. Deshpande AJ, Buske C. Lymphoid progenitors as candidate cancer stem cells in AML: new perspectives. Cell Cycle 2007; 6:543-5; PMID:17329976; DOI:10.4161/cc.6.5.3968.
114. + acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med 2009; 206:3131-41; PMID:19995953; DOI:10.1084/jem.20091050.
115. Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10 and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. Leukemia 2005; 19:734-40; PMID:15789069; DOI:10.1038/sj.leu.2403673.
116. Harrison CJ, Moorman AV, Broadfield ZJ, Cheung KL, Harris RL, Reza Jalali G, et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 2004; 125:552-9; PMID:15147369; DOI:10.1111/j.1365- 2141.2004.04948.x.
117. Hock H, Meade E, Medeiros S, Schindler JW, Valk PJ, Fujiwara Y, et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev 2004; 18:2336-41; PMID:15371326; DOI:10.1101/gad. 1239604.
118. Cleary ML. A new angle on a pervasive oncogene. Nat Genet 1999; 23:134-5; PMID:10508502; DOI:10.1038/13761.
119. Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int J Hematol 2011; PMID: 21537931.
120. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321-30; PMID:8565077; DOI:10.1016/S0092-8674(00)80986-1.
121. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996; 93:3444-9; PMID:8622955; DOI:10.1073/pnas.93.8.3444.
122. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A, et al. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 1996; 16:1349-55; PMID:8657108.
123. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7:823-33; PMID:17957188; DOI:10.1038/nrc2253.
124. Horton SJ, Williams O. The mechanism of hematopoietic progenitor cell immortalization by MLLENL. Cell Cycle 2006; 5:360-2; PMID:16479159; DOI:10.4161/cc.5.4.2464.
125. Meyer C, Schneider B, Jakob S, Strehl S, Attarbaschi A, Schnittger S, et al. The MLL recombinome of acute leukemias. Leukemia 2006; 20:777-84; PMID:16511515; DOI:10.1038/sj.leu.2404150.
126. Ernst P, Fisher JK, Avery W, Wade S, Foy D, Korsmeyer SJ. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev Cell 2004; 6:437-43; PMID:15030765; DOI:10.1016/S1534-5807(04)00061-9.
127. Ernst P, Mabon M, Davidson AJ, Zon LI, Korsmeyer SJ. An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr Biol 2004; 14:2063-9; PMID:15556871; DOI:10.1016/j.cub.2004.11.012.
128. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009; 94:984- 93; PMID:19535349; DOI:10.3324/haematol. 2008.002436.
129. Liu H, Takeda S, Cheng EH, Hsieh JJ. Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia. Cell Cycle 2008; 7:428-35; PMID:18235233; DOI:10.4161/cc.7.4.5426.
130. Aspland SE, Bendall HH, Murre C. The role of E2APBX1 in leukemogenesis. Oncogene 2001; 20:5708- 17; PMID:11607820; DOI:10.1038/sj.onc.1204592.
131. Seidel MG, Look AT. E2A-HLF usurps control of evolutionarily conserved survival pathways. Oncogene 2001; 20:5718-25; PMID:11607821; DOI:10.1038/sj.onc.1204591.
132. Selleri L, Depew MJ, Jacobs Y, Chanda SK, Tsang KY, Cheah KS, et al. Requirement for Pbx1 in skeletal patterning and programming chondrocyte proliferation and differentiation. Development 2001; 128:3543-57; PMID:11566859.
133. Kamps MP, Murre C, Sun XH, Baltimore D. A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 1990; 60:547-55; PMID:1967983; DOI:10.1016/0092-8674(90)90658-2.
134. LeBrun DP, Cleary ML. Fusion with E2A alters the transcriptional properties of the homeodomain protein PBX1 in t(1;19) leukemias. Oncogene 1994; 9:1641-7; PMID:8183558.
135. Lu Q, Wright DD, Kamps MP. Fusion with E2A converts the Pbx1 homeodomain protein into a constitutive transcriptional activator in human leukemias carrying the t(1;19) translocation. Mol Cell Biol 1994; 14:3938-48; PMID:7910944.
136. Van Dijk MA, Voorhoeve PM, Murre C. Pbx1 is converted into a transcriptional activator upon acquiring the N-terminal region of E2A in pre-B-cell acute lymphoblastoid leukemia. Proc Natl Acad Sci USA 1993; 90:6061-5; PMID:8327485; DOI:10.1073/pnas.90.13.6061.
137. Hunger SP, Ohyashiki K, Toyama K, Cleary ML. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev 1992; 6:1608-20; PMID:1516826; DOI:10.1101/gad.6.9.1608.
138. Hitzler JK, Soares HD, Drolet DW, Inaba T, O'Connel S, Rosenfeld MG, et al. Expression patterns of the hepatic leukemia factor gene in the nervous system of developing and adult mice. Brain Res 1999; 820:1-11; PMID:10023025; DOI:10.1016/S0006-8993(98)00999-8.
139. Cobaleda C, Perez-Caro M, Vicente-Duenas C, Sanchez-Garcia I. Function of the zinc-finger transcription factor SNAI2 in cancer and development. Annu Rev Genet 2007; 41:41-61; PMID:17550342; DOI:10.1146/annurev.genet.41.110306.130146.
140. Inukai T, Inoue A, Kurosawa H, Goi K, Shinjyo T, Ozawa K, et al. SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell 1999; 4:343-52; PMID:10518215; DOI:10.1016/S1097-2765(00)80336-6.
141. Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005; 105:3434-41; PMID:15650057; DOI:10.1182/blood-2004-07-2922.
142. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987; 235:85-8; PMID:3541203; DOI:10.1126/science.3541203.
143. Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 1991; 65:1165-75; PMID:2065353; DOI:10.1016/0092-8674(91)90012-N.
144. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto- oncogene. Cell 1991; 65:1153-63; PMID:2065352; DOI:10.1016/0092-8674(91) 90011-M.
145. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5:172-83; PMID:15719031; DOI:10.1038/nrc1567.
146. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453:110-4; PMID:18408710; DOI:10.1038/nature06866.
147. Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009; 27:5202-7; PMID:19770381; DOI:10.1200/JCO.2008.21.6408.
148. Virely C, Moulin S, Cobaleda C, Lasgi C, Alberdi A, Soulier J, et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia 2010; 24:1200-4; PMID:20393504; DOI:10.1038/leu.2010.63.
149. Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med 2009; 206:1739-53; PMID:19620627; DOI:10.1084/jem.20090004.
150. Iacobucci I, Lonetti A, Paoloni F, Papayannidis C, Ferrari A, Storlazzi CT, et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica 2010; 95:1683-90; PMID:20534699; DOI:10.3324/haematol.2009.020792.
151. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446:758-64; PMID:17344859; DOI:10.1038/nature05690.
152. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood 2007; 109:3417-23; PMID:17179230; DOI:10.1182/blood-2006-05-025221.
153. Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 2001; 61:4666-70; PMID:11406533.
154. Nebral K, Denk D, Attarbaschi A, Konig M, Mann G, Haas OA, et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009; 23:134-43; PMID:19020546; DOI:10.1038/leu.2008.306.
155. Strehl S, Konig M, Dworzak MN, Kalwak K, Haas OA. PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13). Leukemia 2003; 17:1121-3; PMID:12764378; DOI:10.1038/sj.leu.2402923.
156. Gimelbrant A, Hutchinson JN, Thompson BR, Chess A. Widespread monoallelic expression on human autosomes. Science 2007; 318:1136-40; PMID:18006746; DOI:10.1126/science.1148910
157. Hentges KE, Weiser KC, Schountz T, Woodward LS, Morse HC, Justice MJ. Evi3, a zinc-finger protein related to EBFAZ, regulates EBF activity in B-cell leukemia. Oncogene 2005; 24:1220-30; PMID:15580294; DOI:10.1038/sj.onc.1208243.
158. Mega T, Lupia M, Amodio N, Horton SJ, Mesuraca M, Pelaggi D, et al. Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors. Cell Cycle 2011; 10:2129-39; PMID:21593590; DOI:10.4161/cc.10.13.16045.
159. Warming S, Suzuki T, Yamaguchi TP, Jenkins NA, Copeland NG. Early B-cell factor-associated zinc-finger gene is a frequent target of retroviral integration in murine B-cell lymphomas. Oncogene 2004; 23:2727-31; PMID:15048087; DOI:10.1038/sj.onc.1207452.
160. Yamasaki N, Miyazaki K, Nagamachi A, Koller R, Oda H, Miyazaki M, et al. Identification of Zfp521/ ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia. Oncogene 2010; 29:1963-75; PMID:20062079; DOI:10.1038/onc.2009.475.
161. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8:945-54; PMID:11948098.
162. Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006; 107:4898-906; PMID:16493008; DOI:10.1182/blood-2005- 09-3596.
163. Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med 2011; 208:1135-49; PMID:21606506; DOI:10.1084/jem.20101947.
164. Hosking FJ, Papaemmanuil E, Sheridan E, Kinsey SE, Lightfoot T, Roman E, et al. Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk. Blood 2010; 115:4472-7; PMID:20231427; DOI:10.1182/blood-2009-09- 244483.
165. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 2009; 41:1006-10; PMID:19684604; DOI:10.1038/ng.430.
166. Prasad RB, Hosking FJ, Vijayakrishnan J, Papaemmanuil E, Koehler R, Greaves M, et al. Verification of the susceptibility loci on 7p12.2, 10q21.2 and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood 2010; 115:1765-7; PMID:20042726; DOI:10.1182/blood-2009-09-241513.
167. Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 2010; 42:492-4; PMID:20453839; DOI:10.1038/ng.585.
168. Treviño LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 2009; 41:1001-5; PMID:19684603; DOI:10.1038/ng.432.
169. Henry CJ, Marusyk A, DeGregory J. Aging-associated changes in hematopoiesis and leukemogenesis: What's the connection? Aging (Albany NY) 2011; 3:643-56; PMID:21765201.
170. INK4a. Nature 2006; 443:421-6; PMID:16957735.
171. Nakada D, Levi BP, Morrison SJ. Integrating physiological regulation with stem cell and tissue homeostasis. Neuron 2011; 70:703-18; PMID:21609826; DOI:10.1016/j.neuron.2011.05.011.
172. Dorshkind K, Montecino-Rodriguez E, Signer RA. The ageing immune system: is it ever too old to become young again? Nat Rev Immunol 2009; 9:57-62; PMID:19104499; DOI:10.1038/nri2471.
173. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004; 5:133-9; PMID:14749784; DOI:10.1038/ni1033.
174. Mehr R, Melamed D. Reversing B cell aging. Aging (Albany NY) 2011; 3:438-43; PMID:21483035.
175. Miller JP, Allman D. The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors. J Immunol 2003; 171:2326-30; PMID:12928378.
176. Mori H, Colman SM, Xiao Z, Ford AM, Healy LE, Donaldson C, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002; 99:8242-7; PMID:12048236; DOI:10.1073/pnas.112218799.
177. Zuna J, Madzo J, Krejci O, Zemanova Z, Kalinova M, Muzikova K, et al. ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia. Blood 2011; 117:368-9; PMID:21212293; DOI:10.1182/ blood-2010-09-309070.
178. Lausten-Thomsen U, Madsen HO, Vestergaard TR, Hjalgrim H, Nersting J, Schmiegelow K. Prevalence of t(12;21)[ETV6-RUNX1]-positive cells in healthy neonates. Blood 2011; 117:186-9; PMID:20713965; DOI:10.1182/blood-2010-05- 282764.
179. Vicente-Dueñas C, Abollo-Jimenez F, Ruiz-Roca L, Alonso-Escudero E, Jimenez R, Cenador MB, et al. The age of the target cell affects B-cell leukaemia malignancy. Aging (Albany NY) 2010; 2:908-13; PMID:21164221.
180. Henry CJ, Marusyk A, Zaberezhnyy V, Adane B, DeGregori J. Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis. Proc Natl Acad Sci USA 2011; 107:21713-8; PMID:21098275; DOI:10.1073/pnas.1005486107.
181. Cobaleda C, Sanchez-Garcia I. Stem cell aging and cancer: Immortal but vulnerable. Cell Cycle 2011; 10; In press; PMID:21191182.
182. Greaves M. Leukemogenesis and ageing: 'fit for transformation'? Aging (Albany NY) 2011; 3:79-80; PMID:21386130.
183. Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh JW, Lacour B, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet 2004; 364:2097-105; PMID:15589307; DOI:10.1016/S0140-6736(04)17550-8.
184. Schüz J, Ahlbom A. Exposure to electromagnetic fields and the risk of childhood leukaemia: a review. Radiat Prot Dosimetry 2008; 132:202-11; PMID:18927133; DOI:10.1093/rpd/ncn270.
185. Henderson MJ, Choi S, Beesley AH, Sutton R, Venn NC, Marshall GM, et al. Mechanism of relapse in pediatric acute lymphoblastic leukemia. Cell Cycle 2008; 7:1315-20; PMID:18418081; DOI:10.4161/cc.7.10.5885.